Trial Profile
Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Irinotecan
- Indications Head and neck cancer
- Focus Therapeutic Use
- 30 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect).
- 30 Jun 2009 Additional lead trial investigator identified as reported by New Jersey Cancer Trial Connect.
- 02 Jun 2009 Interim results from 62 (of 71 enrolled) patients were presented at ASCO 2009.